DLL3-Directed T-Cell Engagement With Tarlatamab in Immune Checkpoint Inhibitor–Refractory Metastatic Mucosal Melanoma
JCO Precision Oncology · 2026-11 · 10 (11)
DOI: 10.1200/po-26-00914 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-11. Verfasst von Valerie Glutsch und 11 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Glutsch, V., Gesierich, A., Gerhard-Hartmann, E., Rosenwald, A., Kneitz, H., Klein, D., Schmitt, D., Frey, A., Bargou, R., Goebeler, M., Goebeler, M., & Hummel, H. (2026). DLL3-Directed T-Cell Engagement With Tarlatamab in Immune Checkpoint Inhibitor–Refractory Metastatic Mucosal Melanoma. JCO Precision Oncology, 10(11). https://doi.org/10.1200/po-26-00914
Vancouver
Glutsch V, Gesierich A, Gerhard-Hartmann E, Rosenwald A, Kneitz H, Klein D, et al. DLL3-Directed T-Cell Engagement With Tarlatamab in Immune Checkpoint Inhibitor–Refractory Metastatic Mucosal Melanoma. JCO Precision Oncology. 2026;10(11). doi:10.1200/po-26-00914
BibTeX
@article{Glutsch2026,
author = {Glutsch, Valerie and Gesierich, Anja and Gerhard-Hartmann, Elena and Rosenwald, Andreas and Kneitz, Hermann and Klein, Detlef and Schmitt, Dominik and Frey, Anna and Bargou, Ralf and Goebeler, Matthias and Goebeler, Marie-Elisabeth and Hummel, Horst-Dieter},
title = {DLL3-Directed T-Cell Engagement With Tarlatamab in Immune Checkpoint Inhibitor–Refractory Metastatic Mucosal Melanoma},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {11},
doi = {10.1200/po-26-00914}
}
EUVIMED